Prognostic factors for progression of liver structural lesions in chronic hepatitis C patients

World Journal of Gastroenterology

Volumn 14, Issue 16, 2008, Pages 2522-2528

  Mendes, Liliana S C ^a   Nita, Marcelo E ^a   Ono Nita, Suzane K ^a   Mello, Evandro S ^a   da Silva, Luiz Caetano ^a   Alves, Venâncio A F ^a   Carrilho, Flair J ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Disease progression; Fibrosis; Hepatitis C; Histology; Interferons

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA2 INTERFERON; INTERFERON RECEPTOR; RIBAVIRIN;

ADULT; AGE DISTRIBUTION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DRUG RESPONSE; FEMALE; HEPATITIS C; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER BIOPSY; LIVER FIBROSIS; LIVER HEMOSIDEROSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTIVARIATE ANALYSIS; PREDICTION; PROGNOSIS;

EID: 47849091969     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.14.2522     Document Type: Article

References (34)

1. Focaccia R, da Conceicao OJ, Sette H Jr, Sabino E, Bassit L, Nitrini DR, Lomar AV, Lorenco R, Vieira De Souza F, Kiffer CR, Santos EB, Gonzales MP, Saez-Alquezar A, Riscal JR, Fischer D. Estimated Prevalence of Viral Hepatitis in the General Population of the Municipality of Sao Paulo, Measured by a Serologic Survey of a Stratified, Randomized and Residence-Based Population. Braz J Infect Dis 1998; 2: 269-284
2. Krug LP, Lunge VR, Ikuta N, Fonseca AS, Cheinquer H, Ozaki LS, Barros SG. Hepatitis C virus genotypes in Southern Brazil. Braz J Med Biol Res 1996; 29: 1629-1632
3. Campiotto S, Pinho JR, Carrilho FJ, Da Silva LC, Souto FJ, Spinelli V, Pereira LM, Coelho HS, Silva AO, Fonseca JC, Rosa H, Lacet CM, Bernardini AP. Geographic distribution of hepatitis C virus genotypes in Brazil. Braz J Med Biol Res 2005; 38: 41-49
4. Carrilho FJ, Correa MCJM. Magnitude of hepatitis B and C in Latin America, in Therapies for Viral Hepatitis, Schinazi RF, Somadossi JP, and Thomas HC, editors. London: International Medical Press, 1998: 25-34
5. El-Serag HB. Hepatocellular carcinoma and hepatitis C in the United States. Hepatology 2002; 36: S74-S83
6. Myers RP, Hilsden RJ, Lee SS. Historical features are poor predictors of liver fibrosis in Canadian patients with chronic hepatitis C. J Viral Hepat 2001; 8: 249-255
7. Friedman SL. Evaluation of fibrosis and hepatitis C. Am J Med 1999; 107: 27S-30S
8. Alter HJ, Seeff LB. Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin Liver Dis 2000; 20: 17-35
9. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997; 349: 825-832
10. Pradat P, Alberti A, Poynard T, Esteban JI, Weiland O, Marcellin P, Badalamenti S, Trepo C. Predictive value of ALT levels for histologic findings in chronic hepatitis C: a European collaborative study. Hepatology 2002; 36: 973-977
11. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002 - June 10-12, 2002. Hepatology 2002; 36: S3-S20
12. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. Hepatology 1994; 20: 15-20
13. Yatsuhashi H, Fujino T, Matsumoto T, Inoue O, Koga M, Yano M. Immunohistochemical analysis of hepatic interferon alpha-beta receptor level: relationship between receptor expression and response to interferon therapy in patients with chronic hepatitis C. J Hepatol 1999; 30: 995-1003
14. Poynard T. Interferon alpha in hepatitis C: a cytokine for reducing fibrosis progression. Eur Cytokine Netw 1997; 8: 319-320
15. Poynard T, Ratziu V, Benmanov Y, Di Martino V, Bedossa P, Opolon P. Fibrosis in patients with chronic hepatitis C: detection and significance. Semin Liver Dis 2000; 20: 47-55
16. Ghany MG, Kleiner DE, Alter H, Doo E, Khokar F, Promrat K, Herion D, Park Y, Liang TJ, Hoofnagle JH. Progression of fibrosis in chronic hepatitis C. Gastroenterology 2003; 124: 97-104
17. Albanis E, Friedman SL. Diagnosis of hepatic fibrosis in patients with chronic hepatitis C. Clin Liver Dis 2006; 10: 821-833
18. Poynard T, Bedossa P. Age and platelet count: a simple index for predicting the presence of histological lesions in patients with antibodies to hepatitis C virus. METAVIR and CLINIVIR Cooperative Study Groups. J Viral Hepat 1997; 4: 199-208
19. Verbaan H, Widell A, Bondeson L, Andersson K, Eriksson S. Factors associated with cirrhosis development in chronic hepatitis C patients from an area of low prevalence. J Viral Hepat 1998; 5: 43-51
20. Tassopoulos NC, Papatheodoridis GV, Katsoulidou A, Delladetsima JK, Sypsa V, Touloumi G, Nikandros M, Hatzakis A. Factors associated with severity and disease progression in chronic hepatitis C. Hepatogastroenterology 1998; 45: 1678-1683
21. Mathurin P, Moussalli J, Cadranel JF, Thibault V, Charlotte F, Dumouchel P, Cazier A, Huraux JM, Devergie B, Vidaud M, Opolon P, Poynard T. Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity. Hepatology 1998; 27: 868-872
22. Koda M, Matunaga Y, Kawakami M, Kishimoto Y, Suou T, Murawaki Y. FibroIndex, a practical index for predicting significant fibrosis in patients with chronic hepatitis C. Hepatology 2007; 45: 297-306
23. Ohta T, Sakaguchi K, Fujiwara A, Fujioka S, Iwasaki Y, Makino Y, Araki Y, Shiratori Y. Simple surrogate index of the fibrosis stage in chronic hepatitis C patients using platelet count and serum albumin level. Acta Med Okayama 2006; 60: 77-84
24. Rubbia-Brandt L, Quadri R, Abid K, Giostra E, Male PJ, Mentha G, Spahr L, Zarski JP, Borisch B, Hadengue A, Negro F. Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. J Hepatol 2000; 33: 106-115
25. Adinolfi LE, Utili R, Andreana A, Tripodi MF, Rosario P, Mormone G, Ragone E, Pasquale G, Ruggiero G. Relationship between genotypes of hepatitis C virus and histopathological manifestations in chronic hepatitis C patients. Eur J Gastroenterol Hepatol 2000; 12: 299-304
26. Westin J, Nordlinder H, Lagging M, Norkrans G, Wejstal R. Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients. J Hepatol 2002; 37: 837-842
27. Wyatt J, Baker H, Prasad P, Gong YY, Millson C. Steatosis and fibrosis in patients with chronic hepatitis C. J Clin Pathol 2004; 57: 402-406
28. Wright TL. Treatment of patients with hepatitis C and cirrhosis. Hepatology 2002; 36: S185-S194
29. Giannini E, Mastracci L, Botta F, Romagnoli P, Fasoli A, Risso D, Faravelli F, Ceppa P, Lantieri PB, Icardi GC, Testa R. Liver iron accumulation in chronic hepatitis C patients without HFE mutations: relationships with histological damage, viral load and genotype and alpha-glutathione S-transferase levels. Eur J Gastroenterol Hepatol 2001; 13: 1355-1361
30. Delladetsima JK, Rassidakis G, Tassopoulos NC, Papatheodoridis GV, Smyrnoff T, Vafiadis I. Histopathology of chronic hepatitis C in relation to epidemiological factors. J Hepatol 1996; 24: 27-32
31. Sobesky R, Mathurin P, Charlotte F, Moussalli J, Olivi M, Vidaud M, Ratziu V, Opolon P, Poynard T. Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. The Multivirc Group. Gastroenterology 1999; 116: 378-386
32. Poynard T, McHutchison J, Davis GL, Esteban-Mur R, Goodman Z, Bedossa P, Albrecht J. Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. Hepatology 2000; 32: 1131-1137
33. Rumi MG, De Filippi F, Donato MF, Del Ninno E, Colombo M. Progressive hepatic fibrosis in healthy carriers of hepatitis C virus with a transaminase breakthrough. J Viral Hepat 2002; 9: 71-74
34. Wiley TE, Brown J, Chan J. Hepatitis C infection in African Americans: its natural history and histological progression. Am J Gastroenterol 2002; 97: 700-706